You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
「B仔股」普遍跑贏大市 康寧傑瑞、基石藥業及微創機械人漲9%-13%
「B仔股」今天普遍跑贏大市,其中基石藥業-B(02616.HK)股價一舉重越10天及20天線(2.65-2.77元),曾飆30%至3.27元遇壓,半日收2.8元,續漲11%,半日成交激增至3,933萬股,已為近幾年罕見。 康寧傑瑞製藥-B(09966.HK)重越10天及20天線,最高見8.47元,半日收8.22元,續漲9.5%。三葉草生物-B(02197.HK)高見1.3元,半日收1.17元,續升7.3%。諾誠健華-B(09969.HK)高見8.38元(暫受制50天線8.48元),半日收8.08元,續升升6.3%。華領醫藥-B(02552.HK)重越20天線,最高見2.17元,半日收2.07元,續升5%。信達生物-B(01801.HK)重越10天線(36.03元),最高見36.65元,半日收36.05元,回升6.2%。 微創機械人-B(02252.HK)續彈13%半日高收21元,股價重越10天及20天線。 康方生物(09926.HK)重越20天線,最高見37.8元,半日收37.2元,續升5%。藍籌醫藥股以翰森(03692.HK)及石藥(01093.HK)升幅較大,半日股價升逾2%-3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account